Evidence map›Paper›PMID 34317016›Full record

ArticleJACC. Case reports2020

Infliximab Treatment of Refractory Cardiac Sarcoidosis.

Majid Asawaeer, Benjamin Widener, Varda Singhal, Matthew J DeVries, Debra J Romberger, Alan R Erickson, Yiannis S Chatzizisis

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Controversies in the Treatment of Cardiac Sarcoidosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Majid AsawaeerDivision of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
Benjamin WidenerDivision of Rheumatology, University of Nebraska Medical Center, Omaha, Nebraska.
Varda SinghalDivision of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
Matthew J DeVriesDivision of Radiology, University of Nebraska Medical Center, Omaha, Nebraska.
Debra J RombergerDivision of Pulmonary and Critical Care Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
Alan R EricksonDivision of Rheumatology, University of Nebraska Medical Center, Omaha, Nebraska.
Yiannis S ChatzizisisDivision of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
University of Nebraska Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment of cardiac sarcoidosis is challenging, as the disease can be refractory to traditional treatment with steroids. Infliximab, a tumor necrosis factor-α inhibitor, has been reportedly used in cardiac sarcoidosis, but published evidence is limited. The potential cardiotoxicity of infliximab and the Food and Drug Administration black-box warning for patients with heart failure have hindered the use of this agent in cardiac sarcoidosis. Here, we report a case of refractory cardiac sarcoidosis successfully treated with infliximab and discuss the important role of fluorine-18-fluorodeoxyglucose positron emission tomography in prognostication and guidance of therapy. (

Indexed as

18F-FDG, fluorine-18–fluorodeoxyglucosecardiac sarcoidosisCMR, cardiac magnetic resonanceCS, cardiac sarcoidosisinfliximabmagnetic resonance imagingPET, positron emission tomographypositron emission tomographyTNF, tumor necrosis factor

Identifiers

PMID34317016
PMCPMC8302154
OpenAlexW3079146893

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.